WE PUBLISH LIMITED NUMBER OF
HIGH IMPACT & DECISION MAKING
RESEARCH & MARKET INTELLIGENCE REPORTS
YEARS in
PUBLISHING
INTELLIGENCE
REPORTS
SATISFIED
CUSTOMERS
WE TRACK NEARLY 4500 ACTIVE DRUG DEVELOPERS WORLDWIDE
AND PUBLISH EXCLUSIVE REPORTS ON
ONCOLOGY & NEUROLOGY DRUG DEVELOPMENT
Drug Development is complex process and requires different set of intelligence as per individual's need. We design two set of Reports - Comprehensive Series and Startups Series, both with slightly different objectives and are released at regular interval of time with updates.
METHEDOLOGY To present with a comprehensive story we closely monitor all year round activities and follows events, press releases, social media etc., for routine updates. Also, we subscribes to a large number of extensive & authentic resources to feed our internal Knowledgebase, which together with our primary research & personal interviews enables us to develop a quality and accurate intelligence, in form of Comprehensive Reports.
Drug Reports
COMPREHENSIVE INTELLIGENCE SERIES
Comprehensive Reports are designed to give complete Drug Discovery & Development outlook in Neurology and Oncology along-with individual indication Pipeline Analysis and targets in development intelligence.
Reports provides individual clinical developmental profiles for all major drug indications. Each profile contains epidemiology, market forecast, current top selling therapies, PhIII pipeline drugs with their clinical trial design & combination drugs, key partners with expected launch.
OmicsX Reports covers worldwide active companies with largest number of active molecules in development.Startup's Reports
IDENTIFY PARTNERS SERIES
Drug Developer’s Startup Series are specially designed to identify early stage researchers, having new ideas capable of changing the face of drug discovery. It covers entrepreneurs established in last few years with size less than $500 Mn USD.
Individual’s Technology, Management, Funding and Partnering capabilities are the major highlights of the reports.
Startups Reports covers largest set of authentic drug developers worldwide with early stage molecules available for partnering and thus is the perfect tool to identify new partnering leads.
LARGEST COVERAGE
GUARANTEED
Each Individual Report creates immense authentic knowledge base (all information with references) on hundreds of proprietary technologies, M&A deals and partnering occurring among startups.
COMMON features
- Worldwide coverage with largest number of active companies under analysis.
- All Individual Companies Profiles, covered in single Report, to cross-check the intelligence generated in the report, with numerous links to justify all information.
- LinkedIn & E-mail IDs of all Key Decision Maker(s), to identify and link with focused executives for partenering & business development opportunities.
Download previous year report
01
Oncology Reports
Data Intelligence Derived from
2500+ Active Cancer Drug Developers.
1100+ Oncology Research supporting CROs
600+ Venture Investors
450+ Oncology Focused Events
Ideas We Stand for:
Global Oncology Clinical Drug Developers 2021
Provides Complete Landscape on 1009 Clinical Stage Oncology Drug Development companies covering their Pipeline for Oncology Indications, Emerging Technologies, Partnering, Deals and Funding.
Price – $ 4400 USD
Released – May 2021
Global Oncology Preclinical Drug Developers 2021
Provides Complete Landscape on 1001 Pre-Clinical Stage Oncology Drug Development companies covering their Pipeline for Oncology Indications, Emerging Technologies, Partnering, Deals and Funding.
Price – $ 4000 USD
Released – April 2021
Oncology Drug Report 2021
Comprises of two Reports and provides Complete Landscape on 2010 Oncology Drug Development Companies Worldwide.
Price – $ 4400 USD + $4000 USD
Released – May 2021
Oncology Drug Report 2020
Provides Complete Landscape on 1600 Oncology Drug Development covering Emerging Technologies, Partnering and Funding Status.
Price – $ 5600 USD
Released – March 2020
Global Top 400 Immuno Oncology Startups 2020
Provides Complete Landscape on Latest Immuno-Oncology Drug Development covering Emerging Technologies, Partnering and Funding Status among Startups.
Price – $ 3200 USD
Released – October 2019
Global Top 500 Oncology Startups 2017
Top 500 Oncology Startups Drug Developers established between 2010-2016.
First Innovative Report Helping You to Early Identify Startups & Partner with Them.
Price – $ 2800 USD
Released – Sep 2016
Oncology Intelligence 2017 – Comprehensive Intelligence Report for Decision Making
Comprehensive Decision Making Intelligence derived from Active 1047 Oncology Drug Developers.
OI 2017 is a key update over previous report OI 2014, as it may covers 220 more oncology drug developers than the previous report. It also abandoned 103 companies, which were earlier covered in OI 2014, which were either acquired/merged or closed during the period.
Price – $ 3400 USD (Save $1000 USD use “FIRST1000” at checkout).
Released – January 2017
Oncology Intelligence 2014 – Comprehensive Intelligence Report for Decision Making
Comprehensive Decision Making Intelligence derived from Active 931 Oncology Drug Developers.
OI 2017 is a key update over previous report OI 2013, as it may covers 3398 more oncology drug developers than the previous report. It also abandoned 91 companies, which were earlier covered in OI 2013, which were either acquired/merged or closed during the period.
Price – NOT FOR SALE / AVAILABLE ON REQUEST
Released – January 2014
Oncology Intelligence 2013 – Comprehensive Intelligence Report for Decision Making
Oncology Intelligence 2013, was the first report in the series derived from Active 624 Oncology Drug Developers.
Price – NOT FOR SALE / AVAILABLE ON REQUEST
Released – January 2013
Oncology Drug Funding 2013
Report for the first time covers ‘ONCOLOGY FOCUSED’ 321 Active Venture Capital Firm Profiles their oncology investment portfolio | Criteria | Geographic focus etc.
Price – Freely Available for Download
Released – March 2013 Check Inside Report Also Check – Venture Investors in Drug Development – CRMOncology Intelligence Report 2017
Comprehensive Intelligence Series
Oncology Intelligence Report 2017, is designed to curtail down the efforts in identifying the real picture of present cancer drug development market, by bringing more authentic data under review and eliminating the undesired information.
Report for the first time identifies and profiles 1052 Active Cancer Drug Development companies from 33 countries worldwide, developing 2500+ cancer-targeting drugs.
ONCOLOGY STARTUPS 2017
Identify Partners Series
We bring you reliable car servicing and the security of knowing the mechanic working on your vehicle is fully trained and qualified.
Every mechanic in our workshop is passes advanced training participates in the Auto-Tech program. Auto-Tech training clinics are held nationwide and conducted by industry experts.
Immuno Oncology Startups 2020
Identify Partners Series
Report for the first time identifies and profiles Top 400 Active Immuno-Oncology Startup companies from 24 different countries worldwide, developing 581 cancer targeting drugs.
This highly precise 334 pages report is designed to keep information intact, informative and self-explanatory. Thus, Immuno-Oncology Startups 2020, will help organizations working on cancer research, to supercharge with lots of new decision-making information and jumpstart current partnering/marketing efforts..
RECENT OFFERINGS :
Starting 2019, all our intelligence reports comes with supporting CRM with complete contact details including social contacts, thus helping buyers to identify new partner companies based on report’s intelligence and connect in minutes using pre-filled Social CRM.
02
Neurology Reports
Data Intelligence Derived from
1000+ Active Neurology Drug Developers
500+ Neurology Research supporting CROs
400+ Venture Investors
150+ neurology Focused Events
Ideas We Stand for:
Global Top 370 Neurology Startups 2020
Highly Innovative and Precise Report designed to Identify and Capture the Outlook of Top 370 Early Stage Neurology Drug Developers present in 26 countries worldwide.
Price – $ 3400 USD
Released – October 2020
Global Top 250 Neurology Startups 2017
Highly Innovative and Precise Report designed to Identify and Capture the Outlook of Top 250 Early Stage Neurology Drug Developers present in 24 countries worldwide.
Price – $ 2400 USD
Released – Nov 2016
Check Inside Report
Releasing Soon – Jan 2020
Neurology Drug Report 2014
First time identifies and profiles 480 Active Neurology focused Drug Development companies.
Creates immense authentic knowledge-base on hundreds of proprietary technologies, M&A deals and partnering occurring in domain in last 10 years.
Price – $ 2900 USD
Released – May 2014
Neurology Venture Funding 2013
Report for the first time covers ‘NEUROLOGY FOCUSED’
210 Active Venture Capital Firm Profiles and their Neurology drug Development investment portfolio | Criteria | Geographic focus etc.
Released – April 2013
Neurology STARTUPS 2017
Identify Partners Series
Neurology Startups 2017 (First Edition), is highly innovative and precise report designed to identify and capture the outlook of early stage neurology drug developers companies present in 24 countries worldwide.
The report provides complete landscape on Top 250 Neurology Drug Developing startups established during 2010-2016.
Neurology Startups 2020
Identify Partners Series
Report for the first time identifies and profiles Top 370 Active Neurology Startups from 29 different countries worldwide, developing 448 molecules targeting Neurological disorders; established between 2010 – 2019; available for bio-partnering.
Single source largest collection of early stage Neurology pipeline; which otherwise is very difficult to identify and map for emerging companies. Report will help you in identifying the present and near-term future of Neurology Drug Discovery and development; thus making it a strong buy.
THIS REPORT IS REVISED & UPDATED EDITION OF NEUROLOGY STARTUPS 2017.
Trusted by
